Abstract 165 Table 1
EndpointsAMR in the First-Month Post-HTx (n=9)AMR at 2–12 Months Post-HTx (n=11)P-Value
Subsequent 5 Year Survival 77.8% 81.8% 0.738
Subsequent 5 Year Freedom from CAV 100.0% 72.7% 0.116
Subsequent 5 Year Freedom from NF-MACE 88.9% 45.5% 0.038
Incidence of Recurrent AMR in the First-Year Post-HTx, % 0.0% 0.0% 1.000